|
|
||||||||
1 Clinical Research Department, 2nd Institute of Physiology, Semmelweis University of Medicine, H-1088 Budapest, Hungary; and 2 Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226-0509
| |
ABSTRACT |
|---|
|
|
|---|
Studies were designed to examine
the hypothesis that the renal medulla of Dahl salt-sensitive (Dahl S)
rats has a reduced capacity to generate nitric oxide (NO), which
diminishes the ability to buffer against the chronic hypertensive
effects of small elevations of circulating ANG II. NO synthase (NOS)
activity in the outer medulla of Dahl S rats (arginine-citrulline
conversion assay) was significantly reduced. This decrease in NOS
activity was associated with the downregulation of protein expression
of NOS I, NOS II, and NOS III isoforms in this region as determined by
Western blot analysis. In anesthetized Dahl S rats, we observed that a
low subpressor intravenous infusion of ANG II (5 ng · kg
1 · min
1) did not
increase the concentration of NO in the renal medulla as measured by a
microdialysis with oxyhemoglobin trapping technique. In contrast, ANG
II produced a 38% increase in the concentration of NO (87 ± 8 to
117 ± 8 nmol/l) in the outer medulla of Brown-Norway (BN) rats.
The same intravenous dose of ANG II reduced renal medullary blood flow
as determined by laser-Doppler flowmetry in Dahl S, but not in BN rats.
A 7-day intravenous ANG II infusion at a dose of 3 ng · kg
1 · min
1 did not
change mean arterial pressure (MAP) in the BN rats but increased MAP in
Dahl S rats from 120 ± 2 to 138 ± 2 mmHg (P < 0.05). ANG II failed to increase MAP after NO substrate was provided by infusion of L-arginine (300 µg · kg
1 · min
1) into the
renal medulla of Dahl S rats. Intravenous infusion of
L-arginine at the same dose had no effect on the ANG
II-induced hypertension. These results indicate that an impaired NO
counterregulatory system in the outer medulla of Dahl S rats makes them
more susceptible to the hypertensive actions of small elevations of ANG II.
Brown-Norway rats; nitric oxide synthase; renal medullary blood flow
| |
INTRODUCTION |
|---|
|
|
|---|
THERE HAS BEEN persistent evidence, albeit indirect, that Dahl salt-sensitive (Dahl S) rats may have a reduced ability to produce nitric oxide (NO) in response to different stimuli such as a high-salt diet and vasoconstrictors (5, 6, 14, 16, 27, 33). These findings are consistent with observations that chronic oral or intravenous administration of L-arginine (L-Arg) prevents salt-induced hypertension in Dahl S rats and normalizes the pressure-natriuresis relationship (31). There is evidence of a reduced ability of NO to block chloride reabsorption in the thick ascending limb in Dahl S rats, which could account in part for the salt sensitivity of blood pressure in this strain (13). Consistent with these findings, it was observed that chronic infusion of L-Arg into the renal medullary interstitial space alone was able to prevent salt-induced hypertension in Dahl S rats at doses that have no effect when infused intravenously (23, 24). Taken together, these data suggest that the renal medulla of Dahl S rats may have both a reduced ability to produce NO in response to various stimuli as well as a reduced responsiveness to NO, but this has not been directly ascertained.
NO production is known to play an important role in the regulation of medullary blood flow (MBF) and arterial blood pressure (7, 22, 26). Several vasoconstrictors, such as ANG II, arginine vasopressin (AVP), and norepinephrine, can stimulate the release of medullary NO, which in turn buffers the vascular actions of these agonists (30, 37, 42, 46). Chronic ANG II infusion in captopril-treated rats was shown to increase NO synthase (NOS) III protein levels in homogenates of whole kidney of Sprague-Dawley rats (15). A moderate reduction of NOS activity within the renal medulla resulting from the infusion of a subpressor dose of NG-nitro-L-arginine methyl ester (L-NAME) into the renal medullary interstitial space was shown to enhance the medullary vasoconstrictor effects to small subpressor elevations of plasma ANG II (46). Chronic intravenous administration of ANG II or AVP administered at a dose that normally does not raise arterial pressure produced a sustained hypertension in rats with blunted medullary NOS activity (36, 37).
Recently, we found that mRNA expression of NOS I and NOS III in the outer medulla of the kidney was significantly less in Dahl S rats compared with Brown-Norway (BN) rats (41). Furthermore, these Dahl S rats exhibited sustained hypertension in response to small, normally subpressor elevations of plasma AVP. It was these observations that motivated the design of the present study to more completely characterize the production of NO.
Therefore, studies were carried out to determine whether Dahl S rats 1) exhibit a reduced medullary expression of NOS protein and NOS enzyme activity, 2) exhibit a reduced elevation of medullary NO in response to ANG II administration, 3) exhibit an exaggerated reduction of MBF in the face of small subpressor elevations of circulating ANG II, and 4) would respond to ANG II chronically like BN rats if L-Arg was administered into the renal medullary interstitial space (e.g., would ANG II-induced hypertension be prevented?).
In these studies, inbred strains of Dahl S rats were compared with an inbred strain of normotensive, salt-insensitive BN rats. These two strains were chosen because extensive genetic and functional data have now been obtained from genetic linkage studies using an intercross of these two strains of rats, both of which were inbred in our department (8, 34). Although comparisons between Dahl S and Dahl salt-resistant (Dahl R) strains could have served the same purpose, the aim of the present study was to compare a rat strain in which the renal medulla had a reduced ability to produce NO to a strain in which administration of ANG II resulted in a clear elevation of medullary NO concentrations.
Both rat strains were maintained on a low-salt (0.4%) diet throughout
all studies. ANG II was infused intravenously for 1 wk to Dahl S and BN
rats at 3 ng · kg
1 · min
1,
a dose that was shown to be nonpressor in Sprague-Dawley rats (36). The ability of systemic administration of ANG II
administered intravenously at a subpressor dose to change MBF and
stimulate medullary NO production was determined first in anesthetized
rats (46). Chronically instrumented rats were then studied
to determine whether blunted medullary NO production in Dahl S rats
would sensitize these animals to the hypertensive actions of small
elevations of circulating ANG II (3 ng · kg
1 · min
1 infused
intravenously for 1 wk) and whether a continuous administration of
L-Arg into the renal medulla of Dahl S rats would return
ANG II hyperresponsiveness to normal.
| |
METHODS |
|---|
|
|
|---|
Twelve-week-old male inbred Dahl S (SS/JrHsdMcw) and BN (BN/SsMcw) rats obtained from colonies maintained at the Medical College of Wisconsin (8) were studied. Rats were given free access to tap water and maintained throughout the study on low-salt rat chow (0.4% NaCl; Dyets, Bethlehem, PA).
NOS enzyme activity in the renal cortex and outer and inner medulla of Dahl S (n = 7) and BN (n = 7) rats. NOS activity in renal homogenates was determined by measuring the conversion of L-[3H]Arg to citrulline using a modification of the radioactive HPLC method originally described by Carlberg (2) and modified by Wu et al. (39). The kidneys from Dahl S and BN rats were rapidly removed from pentobarbital sodium-anesthetized rats and were immersed in ice-cold saline, and the cortex, outer medulla, and inner medulla were separated. The tissue was homogenized in 3 vol of a 20 mM HEPES buffer containing 1 mM EDTA, 1 mM dithiothreitol, 2 mM pepstatin, 1 mM leupeptin, and 0.1 mM phenylmethylsulfonyl fluoride. The homogenate was centrifuged at 3,000 g for 5 min and 11,000 g for 15 min. The supernatant was mixed (2:1) with a suspension of Dowex-50W resin in water at pH 5.5 (HCR-W2, ionic form: Sigma Chemical, St Louis, MO) for 10 min followed by a brief centrifugation (3,000 g) to remove endogenous L-Arg from the homogenate (25). This procedure removed >97% of [3H]Arg counts added to the samples to monitor the efficiency of the Arg removal. It is important to note that the Dowex-50W resin had to be extensively washed with water to remove residual acidity before use. Aliquots of the Dowex-treated homogenates (100 µg protein for inner medulla, 250 µg for outer medulla and cortex) were incubated with L-[3H]Arg (0.2 µCi, 20 µM) in 100 µl of 20 mM HEPES buffer containing 2 mM CaCl2, 1 mM NADPH, 1.5 µg/ml calmodulin, 2.5 µM FAD, 1 µM FMN, 20 µM tetrahydrobiopterin, and 0.4 mM L-proline to inhibit arginase activity (1). Inner medullary samples were incubated for 30 min at 37°C, outer medulla for 60 min, and cortical tissue for 90 min. The reactions were stopped by the addition of 50 µl of 20 mM EGTA. The conversion of L-Arg to L-citrulline after derivatization of the sample with 2 vol of o-phthalaldehyde reagent (P-0532) was determined by reverse phase-HPLC using a 4.6 × 25-cm LC-18-DB column (Supelco), which was eluted isocratically at a rate of 1.5 ml/min using 11.5% methanol, 11.5% acetonitrile, 1% tetrahydrofuran, and 0.1 M KH2PO4 (pH 5.9) as the mobile phase. Products were monitored using a radioactive flow detector (Radiomatic Instruments, Tampa, FL), and the activity was determined from the ratio of counts in the citrulline peak to the sum of the counts in the Arg and citrulline peaks.
NOS protein expression in the outer and inner medulla of Dahl S (n = 5) and BN rats (n = 5). Expression of NOS protein was measured in homogenates of renal inner and outer medulla. Aliquots of 50 µg of the renal outer medullary protein and 25 µg of inner medullary homogenate protein were loaded into each lane and size separated by electrophoresis through an 8% SDS-PAGE gel. The proteins were transferred onto a nitrocellulose membrane (Bio-Rad), blocked overnight at 4°C, and then incubated with a monoclonal anti-NOS I antibody (which cross-reacts with NOS II; Transduction Labs) and a monoclonal anti-NOS III antibody (Transduction Labs) for 2 h at a 1:1,000 dilution as we have previously described (21). Bound primary antibodies were detected with a horseradish peroxidase-labeled secondary antibody (goat anti-mouse IgG; 1:1,000; 2 h) and enhanced chemiluminescence (SuperSignal, Pierce Chemical). The band intensities were quantitated using densitometry (Scion Image, Scion).
Comparison of renal medullary NO concentration ([NO]), mean
arterial pressure, and MBF responses to ANG II (5 ng · kg
1 · min
1)
in anesthetized Dahl S (n = 6) and BN (n = 6) rats.
Rats were anesthetized with Inactin (50 mg/kg ip) and ketamine (33 mg/kg im) and surgically prepared for measurement of renal medullary NO
concentration using the microdialysis/hemoglobin trapping technique
described in our previous studies (43, 46). The
microdialysis probe was perfused at a rate of 2.3 µl/min during a 2-h
equilibration period followed by two 30-min control collection periods
(70 µl/30 min). Then ANG II was infused intravenously at a rate of 5 ng · kg
1 · min
1 for a 1-h
equilibration period, and dialysate fluid was collected during
experimental periods. NO-dependent conversion of oxyhemoglobin to
methemoglobin in the dialysate samples was determined using a
wavelength scanning mode of a DU-640 Beckman spectrophotometer (Beckman Instruments). MBF was measured using an optical
fiber (500 µm; Edmund Scientific) implanted into the renal
medulla to a depth of 5.5 mm. MBF changes were determined using a
Perimed PeriFlux PF3 Flowmeter (Perimed) as described in previous
studies (20, 24, 26).
Chronic measurement of mean arterial pressure in Dahl S (n = 6) and BN rats (n = 6).
Rats were anesthetized with xylazine (2 mg/kg ip) and ketamine (30 mg/kg ip) for implantation of indwelling arterial and venous catheters
that were tunneled subcutaneously to the back of the neck and exited
through a flexible spring for attachment to a swivel over the home cage
as described in detail previously (8, 23). Rats received a
continuous saline intravenous infusion at a rate of 0.25 ml/h, the rate
of delivery subsequently used for the ANG II. One week after surgery,
daily 2-h measurements of mean arterial pressure (MAP) were begun using
an on-line data collection and analysis system (8). After
3 days of stable and reproducible MAP measurements, ANG II (Sigma
Chemical) was infused intravenously at a dose of 3 ng · kg
1 · min
1. Infusion
of ANG II was continued for 7 days with daily MAP measurements made
throughout and 2 days after the cessation of ANG II. Previous studies
in our laboratory have demonstrated that this dose does not elevate
arterial pressure when infused intravenously for 1 wk in
uninephrectomized Sprague-Dawley rats (36).
Effect of medullary vs. intravenous L-Arg
administration on ANG II-induced hypertension in Dahl S (n = 5)
rats.
To assess whether a deficiency in the formation of NO in the renal
medulla sensitizes Dahl S rats to the chronic hypertensive effects of
ANG II, a protocol was designed in which medullary NO production was
enhanced by local renal medullary infusion of L-Arg. Rats
were uninephrectomized to avoid interactions with the contralateral
kidney. One week later, femoral arterial and venous catheters as well
as a renal medullary interstitial catheter were implanted under
anesthesia (22-24). After another week of recovery,
MAP was measured for 2 h daily. After 3 stable control days, the
renal medullary interstitial infusion of L-Arg was begun at
a dose of 300 µg · kg
1 · min
1 in a
volume of 8 µl/min. This dose of L-Arg administered into the renal medulla was shown previously to increase medullary [NO] (43) while having no effect on basal MBF (23,
24). After 3 days of L-Arg infusion, the intravenous
ANG II infusion (3 ng · kg
1 · min
1) was
started and continued for 7 days followed by 2 postcontrol days.
1 · min
1) while
isotonic saline was administered into the medullary interstitial space.
On the 3rd day of intravenous L-Arg infusion, ANG II (3 ng · kg
1 · min
1) was added
to the intravenous infusate for a 7-day period followed by 2 postcontrol days.
Statistics. Data are presented as means ± SE. For statistical comparisons of the chronic experiments, one-way ANOVA for repeated measures was used and Tukey's multiple range test as a post hoc analysis was carried out. One-way ANOVA with Tukey's multiple range test was used for all other comparisons. All statistical analyses were performed on the raw data. P < 0.05 was considered statistically significant.
| |
RESULTS |
|---|
|
|
|---|
NOS enzyme activity in the renal cortex and outer and inner medulla
of Dahl S and BN rats.
As seen in Fig. 1, the NOS enzyme
activity of the Dahl S rats was nearly one-third that of the BN rats in
the outer medulla (1.8 ± 0.4 and 11.6 ± 1 pmol
citrulline · min
1 · mg
protein
1). No differences between the two strains were
found in NOS activity in inner medullary homogenates (60.0 ± 5.6 vs. 49.0 ± 3.0 pmol citrulline · min
1 · mg
protein
1 in BN and Dahl S, respectively). NOS activity in
aliquots of renal cortex homogenates was similar in the two strains
(0.9 ± 0.1 vs. 0.9 ± 0.1 pmol
citrulline · min
1 · mg
protein
1 in Dahl S and BN, respectively).
|
NOS protein expression in the outer and inner medulla of Dahl S and
BN rats.
As can be seen in Fig. 2, the levels of
NOS I, NOS II, and NOS III protein expressed were significantly lower
in the outer medulla of Dahl S than in BN rats, while no significant
differences between the strains were observed in the inner medulla.
Previous studies have indicated little or no expression of any of the
NOS isoforms in homogenates of cortex (21).
|
Comparison of renal medullary [NO], MAP, and MBF responses to ANG
II in anesthetized Dahl S and BN rats.
As seen in Fig. 3A,
intravenous ANG II infusion (5 ng · kg
1 · min
1) given
acutely produced small but consistent reductions of the MBF signal
(~10%) in anesthetized Dahl S rats (P < 0.05), but not in BN rats. These changes were consistent with the results of the
microdialysis studies presented in Fig. 3B, indicating that
ANG II had no effect on medullary [NO] in Dahl S rats, while BN rats
exhibited a 38% [NO] increase (P < 0.05). There was
no difference in the resting medullary [NO] levels of Dahl S and BN
rats (89 ± 3 vs. 87 ± 8 nmol/l, respectively), suggesting
that the deficit was due to the inability of Dahl S rats to increase [NO] with ANG II stimulation. The low dose of ANG II used in this study did not change MAP in either strain of rat in these acute experiments (MAP: 131 ± 3 vs. 134 ± 4 mmHg in Dahl S;
114 ± 3 vs. 118 ± 4 mmHg in BN).
|
Chronic measurement of MAP in intravenous ANG II-infused Dahl S and
BN rats.
A comparison of the pressor effects of a chronic intravenous infusion
of ANG II (3 ng · kg
1 · min
1) in Dahl S
and BN rats is presented in Fig. 4. ANG
II had no effect on MAP over 7 days in BN rats but increased MAP
significantly in Dahl S rats. The pressure increase was sustained
throughout the ANG II infusion, reaching its highest level after 7 days, at which time MAP was 18 mmHg higher than during the control
days. MAP returned to within control level 2 days after cessation of the infusion of ANG II.
|
Effect of medullary vs. intravenous L-Arg
administration on ANG II-induced hypertension in Dahl S rats.
As seen in Fig. 5, a renal medullary
interstitial infusion of L-Arg to increase NO levels
completely blocked the pressor response to ANG II in Dahl S rats. The
same dose of L-Arg infused intravenously did not prevent
this ANG II-induced hypertension in this strain of rats.
|
| |
DISCUSSION |
|---|
|
|
|---|
The present study advances our understanding of the role of renal medullary NO in the development of salt-induced hypertension in the Dahl S rat in several ways. First, it provides direct evidence that in a naturally occurring animal model, the reduced ability of the renal medulla to produce NO can lead to the enhancement of the vasoconstrictor actions of ANG II. Second, this study has demonstrated that if this NO deficit was corrected in the Dahl S rat by the local administration of L-Arg, the hypertensive actions of subpressor amounts of ANG II converted the Dahl S phenotype to that of the BN rat strain.
Evidence and consequences of reduced medullary NOS activity and reduced ability to generate NO responses to ANG II stimulation in Dahl S rats. We have shown previously that lowering of medullary NOS activity with a pharmacological inhibitor (L-NAME) in Sprague-Dawley rats led to hypersensitivity of the medullary vasculature to ANG II (46) and to a salt-sensitive form of hypertension (21). It was also shown that salt-induced hypertension in Dahl S rats could be prevented by medullary L-Arg administration, suggesting indirectly that NO production may be reduced in the Dahl S rat (24). The present study, however, provides direct evidence that, with NOS mRNA reduced in the Dahl S rat (41), there is also a reduction in the protein expression of all three NOS isoforms, most notably in the renal outer medulla. This is turn was accompanied by a significant reduction in NOS enzyme activity and medullary NO tissue concentrations in response to ANG II.
A blunted ability of the renal medulla of Dahl S rats to generate NO in response to ANG II stimulation is of particular interest because this would be expected to reduce the excretion of sodium and thereby shift the chronic pressure relationship (21) by increasing sodium reabsorption in the medullary thick ascending limb (mTAL) as shown by Oritz and Garvin (28). NO reduction may indeed account in part for observations that sodium reabsorption by the thick ascending limb is elevated in Dahl S rats (18, 32, 44). This, in turn, may be related to the production of 20-hydroxyeicosatetraenoic acid (20-HETE) in these epithelial cells because this cytochrome P-450 product of arachidonic acid metabolism has vasoconstrictor actions and reduces sodium reabsorption in the medullary thick ascending limb of Henle (44). This same study showed that Dahl S rats have a reduced capacity to produce 20-HETE in the outer medulla (44). Because NO binds to heme in P-4504A enzymes and inhibits the formation of 20-HETE (35), some of the observed response differences between Dahl S and BN could be influenced by these complex interactions. Preliminary studies in our laboratory also suggest that ANG II increases oxygen free radical production in the outer medulla that would, in part, buffer the actions of ANG II-stimulated NO production (12). NADH oxidase levels are higher in the medulla of Sprague-Dawley rats compared with the cortex (45), and it is possible that Dahl S rats exhibit greater levels of oxidative stress than BN rats. Thus there appear to exist several important pathways whereby the reduction of NOS activity in the outer medulla of Dahl S rats could modify the vasoconstrictor effects of plasma ANG II. A second mechanism leading to decreased sodium excretion could be by the reduction of MBF via enhanced vasoconstrictor effects of ANG II in the presence of reduced levels of NO. The rich density of contractile pericytes surrounding the vasa recta vessels in the outer medulla (29) provides an ideal site for NO regulation of blood flow to both the outer and the inner medulla. We have previously shown that a normally nonhypertensive dose of ANG II produced sustained hypertension when medullary NOS activity was blunted by a chronic medullary infusion of a nonhypertensive dose of L-NAME (36). In this same study, it was also found that MBF was chronically reduced by ANG II in these L-NAME-infused rats (36). Studies by others have found reduced renal excretion of cGMP and nitrate/nitrite (33) in Dahl S rats, suggesting impaired NO synthesis. Ikeda and colleagues (17) found that kidneys of Dahl S rats fed a high-salt diet exhibited lower Ca2+-dependent NOS activity levels than Dahl R rats. Castrop and Kurtz (3) reported a decrease in NOS I gene expression in whole kidney homogenates of Dahl S rats compared with Dahl R rats. Although these previous studies did not distinguish cortical from medullary NO production, it was recently reported that immunohistochemical expression of NOS III was lower in both the renal cortical and medullary tissue of Dahl S rats compared with Dahl R rats (19). The impaired NO synthesis that we have found in the outer medulla of the Dahl S rat may be genetically determined. A genetic cosegregation analysis by Deng and Rapp (11) using an intercross between the Dahl S and Dahl R strains found that it was unlikely that NOS III was segregating with the trait of blood pressure salt sensitivity. In other studies, Deng et al. (9, 10) found that although NOS I or NOS III did not segregate with blood pressure, a blood pressure quantitative trait loci (QTL) for NOS II was suggested. A cosegregation analysis between the Dahl S and BN strains carried out in our laboratory recently identified QTLs for arterial pressure and renal blood flow responses to acetylcholine on chromosomes 4, 10, and 12 (34). Interestingly, all three regions harbor NOS genes (Chr 4-NOS III; Chr 10-NOS II; Chr 12-NOS I). It was found that a positive correlation existed between ANG II-induced changes in blood pressure in rats homozygous for the NOS II allele on chromosome 10 in the F2 generation rats that were homozygous for Dahl S alleles, but not for those homozygous for the BN allele. These data indicated that at least one NOS locus (NOS II) could confer a distinct pressure phenotype to these rats (34). Chen et al. (4) recently identified a single nucleotide transversion in the NOS II gene that produced an amino acid substitution (S714P) between the FAD and flavine mononucleotide binding sites and a restriction fragment length polymorphism, which was present only in Dahl S rats. In subsequent studies from this group, expression of this mutation in COS-7 cells showed a decrease in the Vmax but no change in Km of the enzyme for L-Arg of the mutant NOS II gene. Within the physiological concentration range of L-Arg, the amount of NO produced was reduced in cells transfected with the mutant NOS II compared with the wild type. Accelerated degradation of the mutant gene also appeared to contribute to the diminished NO production in cells expressing the Dahl S NOS II gene (40).Restoration of medullary [NO] by L-Arg prevents subpressor ANG II-induced hypertension in Dahl S rats. It is interesting that the basal NO concentrations within the renal medullary tissue did not differ between the Dahl S and BN rat strains as determined by the oxyhemoglobin microdialysis method. This would suggest that there exists sufficient L-Arg substrate and NOS enzyme activity to maintain resting vascular tone in the renal medulla.
However, administration of L-Arg into the renal medulla prevented ANG II-induced hypertension in the Dahl S rats. These results are consistent with the conclusion that reduced medullary NO production in Dahl S rats contributed importantly to the ANG II hypersensitivity. The antihypertensive effects of the L-Arg administration were almost certainly due to the intrarenal effects of L-Arg because intravenous administration of the same dose of L-Arg failed to reduce the hypertensive effects of ANG II. The dose of L-Arg administered in the present study has been shown to produce an elevation of medullary NO concentration in Sprague-Dawley rats (44). Studies by others have found that salt-induced hypertension in Dahl S rats could be prevented by high-dose oral or systemic administration of L-Arg (5, 6, 16, 31). Miyata et al. (23, 24) demonstrated the importance of the renal medullary impairment of NO production in salt-induced hypertension of Dahl S rats. Specifically, renal medullary interstitial infusion of L-Arg in the same low doses used in the present study protected Dahl S rats from high salt-induced hypertension, whereas D-Arg did not, nor did intravenous administration of the same dose of L-Arg. In summary, the present results indicate that there exists an inherited defect in the ability of the Dahl S rat to produce NO within the outer medulla of the kidney. This defect was manifested by reduced protein expression of all three NOS isoforms, a reduction of NOS enzyme activity, and a failure of medullary NO concentrations to increase in response to ANG II in Dahl S rats. As a consequence, hypertension occurred in Dahl S rats with small elevations of circulating ANG II that had no effect in the BN strain.| |
ACKNOWLEDGEMENTS |
|---|
The authors thank M. M. Skelton for careful review of the manuscript and R. Hagemeier and R. Klum for careful analyses of NOS by HPLC.
| |
FOOTNOTES |
|---|
This work was supported by National Heart, Lung, and Blood Institute Grant HL-29587. M. Szentiványi, Jr., was a visiting postdoctoral fellow from Semmelweis Univ. of Medicine, Budapest, Hungary, with support from OKTA T030245. P. Soares was a visiting fellow from the Dept. of Internal Medicine, State Univ. of Campinas, Campinas, Brazil. C. Moreno is a visiting postdoctoral fellow supported by Fundacion Seneca in Spain.
Address for reprint requests and other correspondence: A. W. Cowley, Jr., Dept. of Physiology, Medical College of Wisconsin, 8701 Watertown Plank Rd., P.O. Box 26509, Milwaukee, WI 53226-0509 (E-mail: cowley{at}mcw.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published April 4, 2002;10.1152/ajpregu.00461.2001
Received 2 August 2001; accepted in final form 29 March 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Carajal, N,
and
Cederbaum SD.
Kinetics of inhibition of rat liver and kidney arginases by proline and branched-chain amino acids.
Biochem Biophys Ceta
870:
181-184,
1986.
2.
Carlberg, M.
Assay of neuronal nitric oxide synthase by HPLC determination of citrulline.
J Neurosci Methods
52:
165-167,
1994[ISI][Medline].
3.
Castrop, H,
and
Kurtz A.
Differential nNOS gene expression in salt-sensitive and salt-resistant Dahl rats.
J Hypertens
19:
1223-1231,
2001[ISI][Medline].
4.
Chen, PY,
Gladish RD,
and
Sanders PW.
Vascular smooth muscle nitric oxide synthase anomalies in Dahl/Rapp salt-sensitive rats.
Hypertension
31:
918-924,
1998
5.
Chen, PY,
and
Sanders PW.
L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats.
J Clin Invest
88:
1559-1567,
1991[ISI][Medline].
6.
Chen, PY,
and
Sanders PW.
Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats.
Hypertension
22:
812-818,
1993
7.
Cowley, AW, Jr.
Role of the renal medulla in volume and arterial pressure regulation.
Am J Physiol Regulatory Integrative Comp Physiol
273:
R1-R15,
1997
8.
Cowley, AW, Jr,
Stoll M,
Kaldunski M,
Kurth TM,
Greene AS,
and
Roman RJ.
Genetically defined risk of salt sensitivity in an intercross of Brown Norway and Dahl S rats.
Physiol Genomics
2:
107-115,
2000
9.
Deng, AY.
Is the nitric oxide system involved in genetic hypertension in Dahl rats?
Kidney Int
53:
1501-1511,
1998[ISI][Medline].
10.
Deng, AY,
and
Rapp JP.
Locus for the inducible, but not a constitutive, nitric oxide synthase cosegregates with blood pressure in the Dahl salt-sensitive rat.
J Clin Invest
95:
2170-2177,
1995[ISI][Medline].
11.
Deng, AY,
and
Rapp JP.
Absence of linkage for "endothelial" nitric oxide synthase locus to blood pressure in Dahl rats.
Hypertension
29:
49-52,
1997
12.
Dickhout, J,
Mori T,
and
Cowley AW, Jr.
Calcium, nitric oxide (NO) and superoxide responses of outer medullary vasa recta to Angiotensin II (AII) (Abstract).
FASEB J
16:
A851,
2002.
13.
García, NH,
Plato CF,
Stoos BA,
and
Garvin JL.
Nitric oxide-induced inhibition of transport by thick ascending limbs from Dahl salt-sensitive rats.
Hypertension
34:
508-513,
1999
14.
He, H,
Kimura S,
Fujisawa Y,
Tomohiro A,
Kiyomoto K,
Aki Y,
and
Abe Y.
Dietary L-arginine supplementation normalizes regional blood flow in Dahl-Iwai salt-sensitive rats.
Am J Hypertens
10:
89S-93S,
1997[Medline].
15.
Hennington, BS,
Zhang H,
Miller TM,
Granger JP,
and
Reckelhoff JF.
Angiotensin II stimulates synthesis of endothelial nitric oxide synthase.
Hypertension
31:
283-288,
1998
16.
Hu, L,
and
Manning DR, Jr.
Role of nitric oxide in regulation of long-term pressure-natriuresis relationship in Dahl S rats.
Am J Physiol Heart Circ Physiol
268:
H2375-H2383,
1995
17.
Ikeda, Y,
Saito K,
Kim JL,
and
Yokoyama M.
Nitric oxide synthase isoform activities in kidney of Dahl salt-sensitive rats.
Hypertension
26:
1030-1034,
1995
18.
Ito, O,
and
Roman RJ.
Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats.
Hypertension
33:
419-423,
1999
19.
Johnson, RJ,
Gordon KL,
Giachelli C,
Kurth T,
Skelton MM,
and
Cowley AW, Jr.
Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat.
J Hypertens
18:
1497-1505,
2000[ISI][Medline].
20.
Lu, S,
Mattson DL,
Roman RJ,
Becker CG,
and
Cowley AW, Jr.
Assessment of changes in intrarenal blood flow in conscious rat using laser-Doppler flowmetry.
Am J Physiol Renal Fluid Electrolyte Physiol
264:
F956-F962,
1993
21.
Mattson, DL,
and
Higgins DJ.
Influence of dietary sodium intake on renal medullary nitric oxide synthase.
Hypertension
27:
688-692,
1996
22.
Mattson, DL,
Lu S,
Nakanishi K,
Papanek E,
and
Cowley AW, Jr.
Effect of chronic renal medullary nitric oxide inhibition on blood pressure.
Am J Physiol Heart Circ Physiol
266:
H1918-H1926,
1994
23.
Miyata, N,
and
Cowley AW, Jr.
Renal intramedullary infusion of L-arginine prevents reduction of medullary blood flow and hypertension in Dahl salt-sensitive rats.
Hypertension
33:
446-450,
1999
24.
Miyata, N,
Zou AP,
Mattson DL,
and
Cowley AW, Jr.
Renal medullary interstitial infusion of L-arginine prevents hypertension in Dahl salt-sensitive rats.
Am J Physiol Regulatory Integrative Comp Physiol
275:
R1667-R1673,
1998
25.
Morindani, BA,
and
Kline RL.
Effect of endogenous L-arginine on the measurement of nitric oxide synthase activity in the rat kidney.
Can J Physiol Pharmacol
74:
1210-1214,
1996[ISI][Medline].
26.
Nakanishi, K,
Mattson DL,
and
Cowley AW, Jr.
Role of renal medullary blood flow in the development of L-NAME hypertension in rats.
Am J Physiol Regulatory Integrative Comp Physiol
268:
R317-R323,
1995
27.
Nishida, Y,
Ding J,
Zhou MS,
Chen QH,
Murakami H,
Wu XZ,
and
Kosaka H.
Role of nitric oxide in vascular hyper-responsiveness to norepinephrine in hypertensive Dahl rats.
J Hypertens
16:
1611-1618,
1998[ISI][Medline].
28.
Oritz, PA,
and
Garvin JL.
Interaction of O2
and NO in the thick ascending limb.
Hypertension
39:
591-596,
2002
29.
Pallone, TL.
Vasoconstriction of outer medullary vasa recta by angiotensin II is modulated by prostaglandin E2.
Am J Physiol Renal Fluid Electrolyte Physiol
266:
F850-F857,
1994
30.
Park, F,
Zou AP,
and
Cowley AW, Jr.
Arginine vasopressin-mediated stimulation of nitric oxide within the rat renal medulla.
Hypertension
32:
896-901,
1998
31.
Patel, AR,
Layne S,
Watts D,
and
Kirchner KA.
L-Arginine administration normalizes pressure natriuresis in hypertensive Dahl rats.
Hypertension
22:
863-869,
1993
32.
Roman, RJ,
and
Kaldunski ML.
Enhanced chloride reabsorption in the loop of Henle in Dahl salt-sensitive rats.
Hypertension
17:
1018-1024,
1991
33.
Simchon, S,
Manger W,
Blumberg G,
Brensilver J,
and
Cortell S.
Impaired renal vasodilation and urinary cGMP excretion in Dahl salt-sensitive rats.
Hypertension
27:
653-657,
1996
34.
Stoll, M,
Cowley AW, Jr,
Tonellato PJ,
Greene AS,
Kaldunski ML,
Roman RJ,
Dumas P,
Schork NJ,
Wang Z,
and
Jacob HJ.
A genomics-system biology map for cardiovascular function.
Science
294:
1723-1726,
2001
35.
Sun, CW,
Alonso-Galicia M,
Taheri MR,
Falck FJ,
Harder DR,
and
Roman RJ.
Nitric oxide-20-hydroxyeicosatetraenoic acid interactin in the regulation of K+ channel activity and vascular tone in renal arterioles.
Circ Res
83:
1069-1079,
1998
36.
Szentiványi, M, Jr,
Maeda CY,
and
Cowley AW, Jr.
Local renal medullary L-NAME infusion enhances the effect of long-term angiotensin II treatment.
Hypertension
33:
440-445,
1999
37.
Szentiványi, M, Jr,
Park F,
Maeda CY,
and
Cowley AW, Jr.
Nitric oxide in the renal medulla protects from vasopressin-induced hypertension.
Hypertension
35:
740-745,
2000
38.
Tan, DY,
Meng S,
and
Manning DR, Jr.
Role of neuronal nitric oxide synthase in Dahl salt-sensitive hypertension.
Hypertension
33:
456-461,
1999
39.
Wu, F,
Park F,
Cowley AW, Jr,
and
Mattson DL.
Quantification of nitric oxide synthase activity in microdissected segments of the rat kidney.
Am J Physiol Renal Physiol
276:
F874-F881,
1999
40.
Ying, WZ,
Zia H,
and
Sanders PW.
Nitric oxide synthase (NOS2) mutation in Dahl/Rapp rats decreases enzyme stability.
Circ Res
89:
317-322,
2001
41.
Yuan, B,
and
Cowley AW, Jr.
Evidence that reduced renal medullary nitric oxide activity of Dahl S rats enables small elevations of arginine vasopressin to produce sustained hypertension.
Hypertension
37:
524-528,
2001
42.
Zou, AP,
and
Cowley AW, Jr.
2-Adrenergic receptor-mediated increase in NO production buffers renal medullary vasoconstriction.
Am J Physiol Regulatory Integrative Comp Physiol
279:
R769-R777,
2000
43.
Zou, AP,
and
Cowley AW, Jr.
Nitric oxide in renal cortex and medulla: an in vivo microdialysis study.
Hypertension
29:
194-198,
1997
44.
Zou, AP,
Drummond HA,
and
Roman RJ.
Role of 20-HETE in elevating loop chloride reabsorption in Dahl SS/Jr rats.
Hypertension
27:
631-635,
1996
45.
Zou, AP,
Li N,
and
Cowley AW, Jr.
Production and actions of superoxide in the renal medulla.
Hypertension
37:
547-553,
2001
46.
Zou, AP,
Wu F,
and
Cowley AW, Jr.
Protective effect of angiotensin II-induced increase in nitric oxide in the renal medullary circulation.
Hypertension
31:
271-276,
1997.
This article has been cited by other articles:
![]() |
N. Li, L. Chen, F. Yi, M. Xia, and P.-L. Li Salt-Sensitive Hypertension Induced by Decoy of Transcription Factor Hypoxia-Inducible Factor-1{alpha} in the Renal Medulla Circ. Res., May 9, 2008; 102(9): 1101 - 1108. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Carlstrom, R. D. Brown, J. Edlund, J. Sallstrom, E. Larsson, T. Teerlink, F. Palm, N. Wahlin, and A. E. G. Persson Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals Am J Physiol Renal Physiol, February 1, 2008; 294(2): F362 - F370. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-L. Tain, G. Freshour, A. Dikalova, K. Griendling, and C. Baylis Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1404 - F1410. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, F. Yi, E. A. dos Santos, D. K. Donley, and P.-L. Li Role of Renal Medullary Heme Oxygenase in the Regulation of Pressure Natriuresis and Arterial Blood Pressure Hypertension, January 1, 2007; 49(1): 148 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. E. Taylor and A. W. Cowley Jr. Effect of renal medullary H2O2 on salt-induced hypertension and renal injury Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1573 - R1579. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Herrera and J. L. Garvin Recent Advances in the Regulation of Nitric Oxide in the Kidney Hypertension, June 1, 2005; 45(6): 1062 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-S. Zhou, E. A. Jaimes, and L. Raij Atorvastatin Prevents End-Organ Injury in Salt-Sensitive Hypertension: Role of eNOS and Oxidant Stress Hypertension, August 1, 2004; 44(2): 186 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-S. Zhou, A. G. Adam, E. A. Jaimes, and L. Raij In Salt-Sensitive Hypertension, Increased Superoxide Production Is Linked to Functional Upregulation of Angiotensin II Hypertension, November 1, 2003; 42(5): 945 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Fenton, C.-L. Chou, S. Ageloff, W. Brandt, J. B. Stokes, and M. A. Knepper Increased collecting duct urea transporter expression in Dahl salt-sensitive rats Am J Physiol Renal Physiol, July 1, 2003; 285(1): F143 - F151. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Persson The kidney and hypertension Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2003; 284(5): R1176 - R1178. [Full Text] [PDF] |
||||
![]() |
A. W. Cowley Jr. Genomics and homeostasis Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2003; 284(3): R611 - R627. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sarkis, K. L. Liu, M. Lo, and D. Benzoni Angiotensin II and renal medullary blood flow in Lyon rats Am J Physiol Renal Physiol, February 1, 2003; 284(2): F365 - F372. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||